Capricor Therapeutics to Participate in BIO Digital 2021 Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative.
Published: May 24, 2021
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules
Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD
Upon closing, Dr. Joseph Tucker will be appointed Enveric Biosciences CEO and David Johnson as Executive Chairman
Management will host a conference call to discuss the transaction on Monday, May 24th at 8:30 a.m. ET
NAPLES, Fla., May 24, 2021 /PRNewswire/
Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into a definitive agreement to acquire
Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into a definitive agreement to acquire
MagicMed Industries Inc. ( MagicMed ), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction.
Through its extensive R&D capabilities at the state-of-the-art facility at the University of Calgary, MagicMed has focused on the discovery and early development of novel drug candidates, structurally related to psychedelics with vastly improved pharmaceutical characteristics and commercial potential for the treatment of neurological and psychological indications. The Psybrary™ is MagicMed s library of novel p